AIM:TSTL

Stock Analysis Report

Executive Summary

Tristel Plc develops, manufactures, and supplies infection and contamination control, and hygiene products in the United Kingdom, Germany, and internationally.


Snowflake Analysis

Flawless balance sheet with solid track record.

Share Price & News

How has Tristel's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TSTL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.1%

TSTL

7.7%

GB Medical Equipment

5.9%

GB Market


1 Year Return

47.3%

TSTL

-1.3%

GB Medical Equipment

-22.7%

GB Market

Return vs Industry: TSTL exceeded the UK Medical Equipment industry which returned -1.6% over the past year.

Return vs Market: TSTL exceeded the UK Market which returned -18.8% over the past year.


Shareholder returns

TSTLIndustryMarket
7 Day7.1%7.7%5.9%
30 Day-11.0%-19.4%-23.1%
90 Day5.6%-19.8%-28.1%
1 Year49.7%47.3%0.5%-1.3%-18.6%-22.7%
3 Year106.1%95.7%4.9%0.2%-13.4%-24.7%
5 Year545.7%454.8%36.1%24.6%1.3%-22.0%

Price Volatility Vs. Market

How volatile is Tristel's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Tristel undervalued compared to its fair value and its price relative to the market?

38.75x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: TSTL (£4.05) is trading above our estimate of fair value (£3.04)

Significantly Below Fair Value: TSTL is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: TSTL is poor value based on its PE Ratio (38.7x) compared to the Medical Equipment industry average (26.7x).

PE vs Market: TSTL is poor value based on its PE Ratio (38.7x) compared to the UK market (12.7x).


Price to Earnings Growth Ratio

PEG Ratio: TSTL is poor value based on its PEG Ratio (4x)


Price to Book Ratio

PB vs Industry: TSTL is overvalued based on its PB Ratio (7.5x) compared to the GB Medical Equipment industry average (2.9x).


Next Steps

Future Growth

How is Tristel forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

9.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TSTL's forecast earnings growth (9.7% per year) is above the savings rate (0.5%).

Earnings vs Market: TSTL's earnings (9.7% per year) are forecast to grow slower than the UK market (15.4% per year).

High Growth Earnings: TSTL's earnings are forecast to grow, but not significantly.

Revenue vs Market: TSTL's revenue (9.3% per year) is forecast to grow faster than the UK market (2.7% per year).

High Growth Revenue: TSTL's revenue (9.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TSTL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Tristel performed over the past 5 years?

18.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TSTL has high quality earnings.

Growing Profit Margin: TSTL's current net profit margins (16.2%) are higher than last year (14.9%).


Past Earnings Growth Analysis

Earnings Trend: TSTL's earnings have grown by 18.1% per year over the past 5 years.

Accelerating Growth: TSTL's earnings growth over the past year (33.2%) exceeds its 5-year average (18.1% per year).

Earnings vs Industry: TSTL earnings growth over the past year (33.2%) exceeded the Medical Equipment industry -7.4%.


Return on Equity

High ROE: TSTL's Return on Equity (19.2%) is considered low.


Next Steps

Financial Health

How is Tristel's financial position?


Financial Position Analysis

Short Term Liabilities: TSTL's short term assets (£11.7M) exceed its short term liabilities (£3.7M).

Long Term Liabilities: TSTL's short term assets (£11.7M) exceed its long term liabilities (£4.6M).


Debt to Equity History and Analysis

Debt Level: TSTL is debt free.

Reducing Debt: TSTL has no debt compared to 5 years ago when its debt to equity ratio was 0.2%.

Debt Coverage: TSTL has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: TSTL has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: TSTL has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if TSTL's debt is covered by short term assets.


Next Steps

Dividend

What is Tristel's current dividend yield, its reliability and sustainability?

1.37%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: TSTL's dividend (1.37%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (2.65%).

High Dividend: TSTL's dividend (1.37%) is low compared to the top 25% of dividend payers in the UK market (7.27%).


Stability and Growth of Payments

Stable Dividend: TSTL's dividend payments have been volatile in the past 10 years.

Growing Dividend: TSTL's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (55.9%), TSTL's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average board tenure


CEO

Paul Swinney (60yo)

27.17s

Tenure

UK£1,642,000

Compensation

Mr. Paul C. Swinney serves as the Chief Executive Officer of Tristel Plc. since 1993 and serves as its Director. Mr. Swinney started his career with Brown, Shipley & Co in 1980. He worked for the European  ...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD2.04M) is above average for companies of similar size in the UK market ($USD741.40K).

Compensation vs Earnings: Paul's compensation has increased by more than 20% in the past year.


Board Members

NamePositionTenureCompensationOwnership
Paul Swinney
CEO & Executive Director27.17yrsUK£1.64m1.05% £1.9m
Elizabeth Dixon
Finance Directorno dataUK£264.00k0.10% £182.3k
Bart Margaretha Leemans
Executive Director1.33yrsUK£231.37k2.1% £3.8m
Paul Barnes
Non-Executive Director15.75yrsUK£43.00k0.78% £1.4m
Bruno Luc Holthof
Non-Executive Chairman0.25yrUK£14.00kno data
David William Orr
Non-Executive Director4.42yrsUK£35.00k0.062% £114.2k
Tom Arthur Jenkins
Senior Independent Non-Executive Director1.17yrsUK£35.00kno data

1.3yrs

Average Tenure

58yo

Average Age

Experienced Board: TSTL's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TSTL insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.6%.


Top Shareholders

Company Information

Tristel Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tristel Plc
  • Ticker: TSTL
  • Exchange: AIM
  • Founded: 1993
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: UK£182.966m
  • Shares outstanding: 45.18m
  • Website: https://www.tristel.com

Number of Employees


Location

  • Tristel Plc
  • Lynx Business Park
  • Unit 1B
  • Snailwell
  • Cambridgeshire
  • CB8 7NY
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TSTLAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPJun 2005

Biography

Tristel Plc develops, manufactures, and supplies infection and contamination control, and hygiene products in the United Kingdom, Germany, and internationally. The company operates through three segments: Human Healthcare, Animal Healthcare, and Contamination Control. It offers hospital infection prevention and control products under the Tristel brand; contamination control products for pharmaceutical and personal care industries under the Crystel brand; and animal health infection prevention and control products under the Anistel brand. Tristel Plc was founded in 1993 and is based in Snailwell, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/27 21:07
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.